{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'The measurements will be done by placing the measurement probe (5 mm in diameter) in contact', 'with the surface of the lesion for a few seconds. The probe will deliver low-intensity white light', 'to the lesion and detect the reflected light. A total of 3-5 measurements will be taken from the', 'center of each lesion, before and immediately after PDT. The data set will be identified by the', \"participant's ID and stored on a secure laptop. The end of the probe will be disinfected after use in\", 'each participant by soaking it in Cidex for 15 minutes following the procedure described in', 'Appendix C.', '8.11 PATHOLOGY', 'At each site, the tumor biopsy will be sent to a surgical pathologist and processed for routine', 'standard of care pathological examination. When tumor-biopsy morphology precludes objective', 'evaluation by histopathology, ancillary immunohistochemical studies may be employed to', 'determine the presence of tumor cells, by the pathologist. (If standard H&E cannot be used to', 'evaluate the presence of tumor cells, the pathologist will use immunohistochemistry to evaluate', 'the biopsy).', '8.12 CLINICAL', 'Dr. Biel, a Project Leader at the University of MN will be available for consultation throughout', 'the study.', 'Ear, Nose & Throat Specialty Care of Minnesota', 'Dr. Merrill Biel', '2211 Park Avenue South', 'Minneapolis, MN 55404', 'Tel. 612-871-2980 or Cellphone: 612-501-8535', 'Fax: 612-871-2012 or E-mail: bielx001@umn.edu', '9', 'EFFICACY EVALUATIONS', '9.1 OBJECTIVE TUMOR RESPONSE', 'Pathological tumor response will be evaluated by taking a 3-mm punch biopsy from the PDT', 'treated or surgical area at 12-16 weeks after PDT or surgery. The participants from the PDT and', 'surgery arms will be followed clinically up to 2 years. At the end of the follow up time, the treating', 'physician will examine the clinical response and a photograph of the treatment site will be taken', 'with paper ruler, to determine the reduction in the lesion size, according to RECIST v1.1. The', 'study coordinator or nurse will take the photos. The treating physician will determine the lesion', \"size with a caliper if photos can't be taken.\", '9.2 TARGET LESIONS', 'All identifiable lesions will be recorded with digital photography and clinical examination. The', 'objective tumor response will be determined according to the following criteria per Recist v1.1', 'Complete Response (CR): Disappearance of all target lesions. Any lymph nodes must', 'have a reduction in short axis to < 10 mm.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 35 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions,', 'taking as reference the baseline sum diameters. A biopsy will be taken from the suspected', 'lesions for histological confirmation of squamous cell carcinoma.', 'Progressive Disease (PD): At least a 20% increase in the sum of diameters of target', 'lesions, taking as references the smallest sum on study (this includes the baseline sum if', 'that is the smallest on study). In addition to the relative increase of 20%, the sum must also', 'demonstrate an absolute increase of at least 5 mm. The appearance of one or more new', 'lesions is also considered progression.', 'Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase', 'to qualify for PD, taking as reference the smallest sum diameters while on study, the', 'response will be listed with stable disease. In this case, a biopsy will be taken from the', 'suspected lesion for histological confirmation.', '9.3 EVALUATION OF RESPONSE', 'Time point response assessments will be performed 12 - 16 weeks and 24 months after PDT. To', 'determine time point response, refer to Table 4 below.', 'Table 4', 'Time Point Response Criteria (+/- non-target disease)', 'Target Lesions', 'Non-Target Lesions', 'New Lesions', 'Overall Response', 'CR', 'CR', 'No', 'CR', 'CR', 'Non-CR/Non-PD', 'No', 'PR', 'CR', 'Not evaluated', 'No', 'PR', 'PR', 'Non-PD or not all evaluated', 'No', 'PR', 'SD', 'Non-PD or not all evaluated', 'No', 'SD', 'Not all evaluated', 'Non-PD', 'No', 'NE', 'PD', 'Any', 'Yes or No', 'PD', 'Any', 'PD', 'Yes or No', 'PD', 'Any', 'Any', 'Yes', 'PD', 'The best overall response is the best response recorded from the start of study treatment until', 'follow-up is completed or the participant goes off study (the end of treatment taking into account', 'any requirement for confirmation).', 'Symptomatic Deterioration: Participants with global deterioration of health status requiring', 'study withdrawal without objective evidence of disease progression at that time, and not related', 'to study treatment or other medical conditions should be reported as progressive disease due', 'to \"symptomatic deterioration.\" Every effort should be made to document objective', 'progression even after discontinuation of treatment due to symptomatic deterioration.', 'Symptomatic deterioration that may lead to study withdrawal includes, but is not limited to,', 'symptoms such as:', 'Weight loss > 10% of body weight.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 36 of 64']\n\n###\n\n", "completion": "END"}